[{"orgOrder":0,"company":"American Heart Association","sponsor":"Janssen Scientific Affairs","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Canagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"American Heart Association","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"American Heart Association \/ Janssen Scientific Affairs","highestDevelopmentStatusID":"10","companyTruncated":"American Heart Association \/ Janssen Scientific Affairs"}]

Find Clinical Drug Pipeline Developments & Deals by American Heart Association

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Adults with heart failure who took canagliflozin, a medication originally developed to treat type 2 diabetes, reported improvements in their heart failure symptoms whether or not they also had type 2 diabetes.

                          Brand Name : JNJ-28431754

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 14, 2021

                          Lead Product(s) : Canagliflozin

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Janssen Scientific Affairs

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank